Embracing value-based partnerships: A path to enhanced healthcare outcomes

Manufacturers

From Potential to Value: Carving a Slice of the CGT ‘PIE'

From PICO anxiety to PICO strategy: planning for EU HTA success

Webinar on-demand - A Panel Discussion on Navigating Medical Devices in Canada

Manufacturers

Forging ahead with US and EU healthcare policy changes: balancing sustainability, innovation and patient access in the era of IRA and EU HTA

Manufacturers

Recap AMCP 2024: Our thought leadership in action

Manufacturers

Webinar: Bracing for the Impact of Biosimilars: Navigating Terrain in the U.S. Market Landscape

Q&A Interview: Navigating the launch of ATMPs in Europe

Manufacturers

Benefit-driven pricing: How AMNOG strikes a balance between the financial burden on statutory health insurance and reimbursement of innovative medications in Germany

Manufacturers

Embarking on the EU HTAR realization journey: Key insights from the first of six implementing acts

Manufacturers

EAMS evidence: A key player in drug value proposition and NICE approval?

Manufacturers

HTAQ Summer 2024

Manufacturers

Government Reliance on Value Assessments in Medicare Part B

Manufacturers

Rating the robots: Artificial intelligence for literature reviews

Manufacturers

It’s Just…So…Cool – Don’t miss your opportunity for JSC!

Manufacturers

Apples to apples, or apples to oranges? Comparing the Inflation Reduction Act to drug-pricing programs in other countries

Manufacturers

Anticipating the top seven global market access trends for 2024: Cencora’s healthcare landscape outlook 

Manufacturers

Patients at the center – Does the JCA truly embrace the patients’ voice?

Manufacturers

Unlocking the Potential of Joint Clinical Assessment (JCA) in Europe: Insights from Industry Leaders and Experts

Manufacturers

Webinar on demand: Implications of the EU JCA on patient access and engagement

Manufacturers

Does the EU HTAR really put patients at the center?

Manufacturers

The more things change, the more they stay the same? Reviewing ICER's revised value assessment framework

Manufacturers

Navigating the way to the new EU JCA—Are biopharma companies, HTA bodies, patients, and clinicians sufficiently prepared? 

Manufacturers

How NICE there’s an app for that! 

Manufacturers

Gauge the impact: What does the striking down of a federal copay accumulator regulation mean for patients and copay programs?

Manufacturers

First 10 drugs for Medicare price negotiation announced under IRA

Manufacturers

Podcast: Collaborative perseverance to bring change to medicine access

Pharmacies

3 ways your distributor can help you prepare for DSCSA compliance

Manufacturers

Recap AMCP 2023: Our thought leadership in action

Manufacturers

Optimize your pre-approval information exchange strategy

Evolving ATMP regulations require news logistics complexity

Regulators tighten CGT logistics for patient safety and security

Manufacturers

HTA Quarterly | Spring 2023

Cell and gene therapy regulatory framework in Europe

Pharmacies

DSCSA: Are you ready for November 2024?

Manufacturers

Education: The centerpiece of biosimilar adoption

With landmark approval, spotlight on cryogenic logistics intensifies

Manufacturers

HTA Quarterly | Summer 2023

Manufacturers

HTA Quarterly | Winter 2022

Manufacturers

Podcast: Conversations around interchangeability and biosimilar entries in new therapeutic categories

Manufacturers

Closing the gaps in pre-approval information exchange to accelerate product success and patient access

Manufacturers

Market access abroad: Three reasons why early planning is critical for HTA countries

Manufacturers

Podcast: Milestones for biosimilars in 2022 and looking ahead to 2023

Patients lose if we don't continue to expand pharmacy-based clinical care in the U.S.

Webinar: Debunking common PIE misperceptions to enhance your PIE strategy and tactics

Physician Practices

Q&A: Legislative updates and healthcare advocacy report

Manufacturers

Health policy and the political landscape

Affordability is about more than drug prices

Manufacturers

The Value of Real-World Evidence in Canadian Drug Commercialization: Part 2

Manufacturers

Strategies for addressing copay accumulators: What manufacturers need to know

Let's Ditch 2020 and Plan for 2021: Election What-Ifs

Health Systems

Biosimilars: Patents, policy, and reimbursement

Physician Practices

COVID-19 Resources

Manufacturers

Commercializing in Canada: Quality Assurance and GMP Services

Manufacturers

Commercializing in Canada: Regulatory Publishing and Submissions

Physician Practices

How COVID-19 is Altering Telehealth

Physician Practices

Cybersecurity and Working Virtually During the Pandemic

Health Systems

Partnering With Your Distributor for USP 800 Compliance

Manufacturers

Mind the (Evidence) Gap

Manufacturers

InnomarLive 2019: Commercializing in Canada